It has been performed already as CD16/CD30 bispecific (AFM13), and the efficacy of such a strategy is currently being explored in phase II clinical trial for relapsed/refractory CD30+ T-cell lymphoma or transformed mycosis fungoides (NCT04101331). This evidence concerns the gene TNFRSF8 and mycosis fungoides.